BioXcel Therapeutics (BTAI) Receivables - Net (2022 - 2025)
BioXcel Therapeutics (BTAI) has 4 years of Receivables - Net data on record, last reported at $17000.0 in Q2 2025.
- For Q2 2025, Receivables - Net fell 97.91% year-over-year to $17000.0; the TTM value through Jun 2025 reached $17000.0, down 97.91%, while the annual FY2024 figure was $131000.0, 84.51% up from the prior year.
- Receivables - Net reached $17000.0 in Q2 2025 per BTAI's latest filing, down from $131000.0 in the prior quarter.
- Across five years, Receivables - Net topped out at $812000.0 in Q2 2024 and bottomed at $3000.0 in Q3 2024.
- Average Receivables - Net over 4 years is $310900.0, with a median of $265500.0 recorded in 2022.
- The widest YoY moves for Receivables - Net: up 88.4% in 2024, down 99.59% in 2024.
- A 4-year view of Receivables - Net shows it stood at $248000.0 in 2022, then tumbled by 71.37% to $71000.0 in 2023, then soared by 84.51% to $131000.0 in 2024, then plummeted by 87.02% to $17000.0 in 2025.
- Per Business Quant database, its latest 3 readings for Receivables - Net were $17000.0 in Q2 2025, $131000.0 in Q4 2024, and $3000.0 in Q3 2024.